Literature DB >> 17690569

Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.

Andrew N Phillips1, Brian Gazzard, Richard Gilson, Philippa Easterbrook, Margaret Johnson, John Walsh, Clifford Leen, Martin Fisher, Chloe Orkin, Jane Anderson, Deenan Pillay, Valerie Delpech, Caroline Sabin, Achim Schwenk, David Dunn, Mark Gompels, Teresa Hill, Kholoud Porter, Abdel Babiker.   

Abstract

OBJECTIVE: To assess the absolute rate of AIDS and death in antiretroviral therapy (ART)-naive patients with a high CD4 cell count. Such information would be helpful in the design of a trial investigating early initiation of ART.
DESIGN: Analysis of data from an ongoing HIV cohort study.
METHODS: The rate of (severe) AIDS or death and death alone was evaluated in ART-naive patients according to the current CD4 cell count, focusing on CD4 cell counts > or = 350 cells/microl among patients in the UK CHIC Study.
RESULTS: In a total of 30 313 person-years of follow-up, there were 1557 AIDS or death events. The rate of AIDS or death in persons with most recent CD4 cell count 350-499, 500-649 and > 650 cells/microl was 2.49, 1.54 and 0.96 per 100 person-years, respectively. The rate ratio for those with CD4 cell count 500-649 cells/microl compared with those with CD4 cell count > or = 650 cells/microl was 1.55 [95% confidence interval (CI), 1.11-2.17; P = 0.01]. In a Poisson regression model based on person years with CD4 cell count > or = 350 cells/microl , there was a strong effect of CD4 cell count on rate of AIDS or death (rate ratio, 0.84; 95% CI, 0.76-0.93; P = 0.001), independent of viral load and age.
CONCLUSIONS: The trend of decreasing rate of AIDS and death with higher CD4 cell count is present throughout the CD4 cell count > or = 350 cells/microl range in ART-naive people.

Entities:  

Mesh:

Year:  2007        PMID: 17690569     DOI: 10.1097/QAD.0b013e32827038bf

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  43 in total

1.  Considerations for Endpoint Selection When Designing HIV Clinical Trials.

Authors:  Katherine Huppler Hullsiek; Birgit Grund
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

2.  Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.

Authors:  Alan Winston; Chris Duncombe; Patrick C K Li; John M Gill; Stephen J Kerr; Rebekah L Puls; Simon D Taylor-Robinson; Sean Emery; David A Cooper
Journal:  Neuroradiology       Date:  2012-07-07       Impact factor: 2.804

3.  Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness.

Authors:  Ashish A Deshmukh; Elizabeth Y Chiao; Scott B Cantor; Elizabeth A Stier; Stephen E Goldstone; Alan G Nyitray; Timothy Wilkin; Xiaojie Wang; Jagpreet Chhatwal
Journal:  Cancer       Date:  2017-09-26       Impact factor: 6.860

Review 4.  Antiretroviral therapy for prevention is a combination strategy.

Authors:  Margaret L McNairy; Myron Cohen; Wafaa M El-Sadr
Journal:  Curr HIV/AIDS Rep       Date:  2013-06       Impact factor: 5.071

5.  Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.

Authors:  Stephen R Cole; Sonia Napravnik; Michael J Mugavero; Bryan Lau; Joseph J Eron; Michael S Saag
Journal:  Am J Epidemiol       Date:  2009-12-09       Impact factor: 4.897

6.  Immunologic and virologic events in early HIV infection predict subsequent rate of progression.

Authors:  Anuradha Ganesan; Pratip K Chattopadhyay; Tess M Brodie; Jing Qin; Wenjuan Gu; John R Mascola; Nelson L Michael; Dean A Follmann; Mario Roederer
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

7.  Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.

Authors:  Damalie Nakanjako; Agnes N Kiragga; Beverly S Musick; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Lameck Diero; Patrick Oyaro; Emanuel Lugina; John C Ssali; Andrew Kambugu; Philippa Easterbrook
Journal:  AIDS       Date:  2016-07-31       Impact factor: 4.177

8.  The therapeutic implications of timely linkage and early retention in HIV care.

Authors:  Kimberly B Ulett; James H Willig; Hui-Yi Lin; Justin S Routman; Sarah Abroms; Jeroan Allison; Ashlee Chatham; James L Raper; Michael S Saag; Michael J Mugavero
Journal:  AIDS Patient Care STDS       Date:  2009-01       Impact factor: 5.078

9.  Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.

Authors:  Andrew M Abaasa; Jim Todd; Kenneth Ekoru; Joan N Kalyango; Jonathan Levin; Emmanuel Odeke; Charles A S Karamagi
Journal:  BMC Health Serv Res       Date:  2008-11-20       Impact factor: 2.655

10.  Impact of housing on the survival of persons with AIDS.

Authors:  Sandra K Schwarcz; Ling C Hsu; Eric Vittinghoff; Annie Vu; Joshua D Bamberger; Mitchell H Katz
Journal:  BMC Public Health       Date:  2009-07-07       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.